Knight Therapeutics (TSE:GUD) Posts Earnings Results

Knight Therapeutics (TSE:GUD) released its earnings results on Thursday. The company reported C$0.13 earnings per share for the quarter, FiscalAI reports. The firm had revenue of C$147.59 million for the quarter. Knight Therapeutics had a negative net margin of 1.19% and a negative return on equity of 0.70%.

Here are the key takeaways from Knight Therapeutics’ conference call:

• Reported record Q1 results with CAD 148 million in revenues (≈69% YoY growth) and CAD 28 million adjusted EBITDA (≈130% YoY), driven by acquired portfolios and promoted products.
• Raised 2026 guidance to CAD 510–525 million in revenues and targeted adjusted EBITDA of ~15% of revenues, citing stronger promoted-product performance and improved LatAm FX.
• Pipeline and commercialization momentum: regulatory submissions for Niktimvo (Brazil) and Minjuvi (Argentina, Mexico), Brazilian approval of Minjuvi’s second indication, four launches completed in 2026 so far and management expects roughly ~10 launches in 2026.
• Withdrew the Health Canada NDS for Kalbi due to partner manufacturing changes; resubmission and launch are expected later (management estimated a ~1–2 year delay), deferring near-term Canadian revenue from this product.
• Balance sheet and cash flow strengthened: CAD 127 million in cash/marketable securities, net cash of ~CAD 69 million, CAD 41 million operating cash inflow in Q1, ongoing NCIB purchases and capacity to fund further BD/acquisitions.

Knight Therapeutics Stock Up 11.2%

TSE GUD traded up C$0.84 on Thursday, hitting C$8.35. 355,070 shares of the stock were exchanged, compared to its average volume of 94,432. The company has a quick ratio of 1.79, a current ratio of 2.39 and a debt-to-equity ratio of 10.15. Knight Therapeutics has a fifty-two week low of C$5.50 and a fifty-two week high of C$8.50. The company has a market cap of C$818.77 million, a PE ratio of -167.00, a PEG ratio of -1,013.50 and a beta of -0.21. The company has a 50-day moving average price of C$7.03 and a 200-day moving average price of C$6.36.

About Knight Therapeutics

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.